NEW YORK, Aug. 18, 2015 /PRNewswire/ -- INTRODUCTION
Cancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body's own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). These antibody based drugs are passive immunotherapeutics. There has been a surge of interest in other classes of active immunotherapeuticsincludingcell based therapies such as Dendritic Cell Therapy (DCT) and Chimeric Antigen Receptor T cell Therapy (CAR-T).
DCTmakes use of autologous or allogenic Antigen Presenting Cells (APCs) to stimulate the immune systemto recognise and act against the tumors. In April 2010, the FDA approval of Sipuleucel-T (PROVENGE, manufactured by Dendreon Corporation), a dendritic cell vaccine, gave a push to the concept of DCT. However, the vaccine hasn't been able to meet the high expectations. Despite this, the overall DCT outlook is promising; late stage development vaccines such as AGS-003, DCVax-L, DCVAC/PCa and Eltrapuldencel-T are likely to carry forward the baton.
With the similar aim to stimulate the body's immune system, CAR-T uses the patient's autologous effector T-cells, modifying it with a synthetic receptor enabling it to increase the tumor specific immune response. This therapy is expected to first enter market with the launch of CTL019 by Novartis in the next few years. In recent trials, CTL019 has shown complete remission in children with advanced cases of treatment-resistant ALL. Apart from Novartis, some other big pharmaceutical companies including Pfizer have entered the space. Juno Therapeutics, Takara Bio and Kite Pharma are other active players.
We anticipate the market to continue to rise steadily as several DC vaccines and CAR-T cell therapies get approval, both as monotherapy and combination therapy.
SCOPE OF THE REPORT
The 'Dendritic Cell and CAR-T Therapies Market, 2014-2024' report provides an extensive study on the two Whole Cell based Immunotherapies: Dendritic Cell Therapy (DCT) and Chimeric Antigen Receptor (CAR) T-cell Therapy. These upcoming fields of therapeutics are still in infancy, with only two DCT vaccines commercially available in 2014. The report covers various aspects, such as, existing cancer immunotherapeutics, main players in the DCT and CAR-T industry, products in clinical / pre-clinical research, technological developments and upcoming opportunities for several stakeholders.
As pharma companies continue to expand their research programs in this area, one of the key objectives outlined for this report is to understand the future potential of the market. This is done by analysing
- DCT and CAR-T pipeline in terms of phase of development, target indications, types of molecule, etc.
- Companies participating in the development of these products highlighting their product portfolio, financial performance, patents, recent collaborationsand future outlook.
- Interest of venture capital firms and recent funding rounds of small biotech firms developing whole cell based immunotherapies.
- Competitive landscape and inherent threats to growth in the short and long term.
- Development and sales potential based on target consumer segments, likely adoption rate and expected pricing.
The report gives an estimate of the short-mid term and long term markets for the period 2014 - 2024. The research, analysis and insights presented in this report include potential sales of the marketed DCT vaccine (PROVENGE) and eight pipeline products in late phases of development.
Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.
All actual figures have been sourced and analysed from publicly available information and discussions with industry experts. The figures mentioned in this report are in USD, unless otherwise specified.
1. CreaVax-RCC (by JW CreaGene) became the first approved dendritic cell vaccine in 2007. However, its market has been restricted to South Korea. PROVENGE (by Dendreon) received FDA approval for launch in the US in 2010.
2. In addition, we have identified 30 dendritic cell vaccines and 12 CAR-T therapies which are currently in clinical and preclinical development for different oncological indications. Of these, four dendritic cell vaccines are in Phase III trials. Majority of the CAR-T therapies are in early stages of development.
3. The market is characterised by the presence of several small biotech firms; these firmsare likely to benefit as more molecules reach advanced stages of development in the coming few years.
4. There has been a growing interest from Venture Capital firms. In fact, in 2013 / 2014, several companies involved in DCT and CAR-T therapies have cumulatively raisedover USD 500 million in venture funding rounds; this activity is likely to increase further and will help these companies drive their respective products to commercialisation.
5. We expect dendritic cell and CAR-T therapies market to be a multi-billion dollar market over the coming decade; during the period 2014 – 2024, our forecast suggests that the market will witness an annualised rate of 29.8%.
Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Industry analysts' views
While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
Chapter 2 presents an executive summary of the report. The summary offers an insight to key highlights of the whole cell based immunotherapies and where the market is headed in the mid-long term.
Chapter 3 provides a general introduction to the market. In this section, we have briefly discussed the conventional therapies being used for oncology treatment, the advent of cancer immunotherapy and, specifically, the emergence DCT and CAR-T.
Chapter 4 provides a comprehensive landscape of the whole cell based immunotherapy market. This chapter includes information on over 40 molecules which are currently in different stages of development (both clinical and pre-clinical / discovery). The detailed analysis of this development pipeline includes information on therapy class, most commonly targeted indications and current phases of development.
Chapter 5focuses on DCT and presents the current scenario and the future outlook of this specific class of vaccines. The chapter includes detailed profiles of marketed and late stage products. We have presented information on several parameters such as history of development, clinical trial results, manufacturing, cost and reimbursement. It includes the likely sales forecast of the drugs currently in Phase III or higher stage of development.
Chapter 6focuses on CAR-T and presents the current scenario and the future outlook of this therapy. As with DCTs, this chapter provides a holistic view on the various cell therapy products belonging to CAR-Ts and their future sales potential.
Chapter 7provides the detailed company profiles of the leading players in the market. Each company profile includes information on financial performance, geographical presence, marketed / pipeline drugs, recent collaborations and developments.
Chapter 8 is a collection of interview transcript(s)of the discussions which were held during the course of this study.
Chapter 9 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Chapters 10 and 11 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.
Read the full report: http://www.reportlinker.com/p02510954-summary/view-report.html
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001